{"id":3144,"date":"2017-09-19T15:15:47","date_gmt":"2017-09-19T19:15:47","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/"},"modified":"2026-09-24T00:09:54","modified_gmt":"2026-09-24T04:09:54","slug":"gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/","title":{"rendered":"GenSight Biologics int\u00e8gre les indices  CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext"},"content":{"rendered":"\n<strong>Paris, le 19 septembre 2017, 7h30 CET \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir int\u00e9gr\u00e9, \u00e0 compter du 18 septembre 2017, les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable suite \u00e0 leur r\u00e9vision annuelle par le Conseil Scientifique des Indices d\u2019Euronext Paris.\n\n<strong>Thomas Gidoin<\/strong>, Directeur Administratif et Financier de GenSight Biologics, a comment\u00e9, \u00ab Un peu plus d\u2019un an apr\u00e8s nos premiers pas en bourse sur Euronext Paris, l\u2019int\u00e9gration aux indices de la famille CAC vient renforcer la visibilit\u00e9 du titre, et potentiellement sa liquidit\u00e9. \u00bb\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intravitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, le 19 septembre 2017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir int\u00e9gr\u00e9, \u00e0 compter du 18 septembre 2017, les [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3144","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, le 19 septembre 2017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir int\u00e9gr\u00e9, \u00e0 compter du 18 septembre 2017, les [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-19T19:15:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:54+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext\",\"datePublished\":\"2017-09-19T19:15:47+00:00\",\"dateModified\":\"2026-09-24T04:09:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/\"},\"wordCount\":330,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/\",\"name\":\"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-09-19T19:15:47+00:00\",\"dateModified\":\"2026-09-24T04:09:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/09\\\/19\\\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext - GenSight Biologics","og_description":"Paris, le 19 septembre 2017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir int\u00e9gr\u00e9, \u00e0 compter du 18 septembre 2017, les [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/","og_site_name":"GenSight Biologics","article_published_time":"2017-09-19T19:15:47+00:00","article_modified_time":"2026-09-24T04:09:54+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext","datePublished":"2017-09-19T19:15:47+00:00","dateModified":"2026-09-24T04:09:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/"},"wordCount":330,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/","name":"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2017-09-19T19:15:47+00:00","dateModified":"2026-09-24T04:09:54+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/09\/19\/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics int\u00e8gre les indices CAC\u00ae Small, CAC\u00ae Mid and Small et CAC\u00ae All-Tradable d\u2019Euronext"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3144"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3144"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3144"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3144"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3144"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}